MD-ZEROFOX
6.10.2020 15:02:14 CEST | Business Wire | Press release
ZeroFOX , the global leader in Digital Risk Protection, is proud to announce the acquisition of the Cyveillance business from LookingGlass Cyber Solutions, Inc™. The Cyveillance team has over 20 years of experience delivering comprehensive threat intelligence services, protecting the corporate brands, executives, and data of the world's largest and most respected financial services, energy, and public sector organizations. The combination of the ZeroFOX Artificial Intelligence-powered Digital Risk Protection Platform with Cyveillance’s comprehensive threat intelligence data lake and expansive human dark web intelligence capabilities positions ZeroFOX as the world leader in Digital Risk Protection, connecting automated protection and intelligence for organizations of all sizes.
“Our merger with the Cyveillance team fulfills our strategic vision of accelerating our position as the definitive worldwide leader in Digital Risk Protection,” said James C. Foster, CEO of ZeroFOX. “The addition of Cyveillance allows us to further scale our Digital Risk Protection services and expand our threat intelligence capabilities, complementing our renowned AI & remediation capabilities, to address the entire digital threat lifecycle. Our combined customer base and over 400 employees makes us the largest, most proven provider in the Digital Risk Protection market, serving the needs of the world’s most recognized brands.”
Organizations today operate in a world that demands a digital-first approach. The dramatic shift creates a global digital footprint and attack surface on social media, mobile applications, websites, and other external digital platforms. This unprotected public attack surface exposes organizations and their communities to targeted cyber-attacks, data loss, phishing scams, compliance violations, and account takeovers.
“ZeroFOX’s cyber platform powered by Artificial intelligence and Machine Learning is truly impressive. It was clear that we needed to bring these two organizations together to achieve scale overnight to benefit our customers,” said Gilman Louie, co-founder of Alsop Louie and Executive Chairman of LookingGlass Cyber Solutions. “Combined with the rich Cyveillance data, human and machine intelligence and expertise, our customers will now be fully equipped to combat growing digital threats and exert security control back into digital experiences. This new powerhouse company will enable customers to achieve a new level of protection that is unique in the industry. Foster has built a world-class team and I am excited to join it and the ZeroFOX Board of Directors.” Louie serves as the commissioner for the United States National Security Commission for Artificial Intelligence and Chairman of the Federation of American Scientists.
While the scale of threats targeting public platforms makes it difficult for security teams to create actionable intelligence and seek timely remediation, the combined power of the ZeroFOX Digital Risk Protection Platform and Cyveillance’s customer-centric Digital Risk Protection services will give customers unparalleled visibility, analysis, and remediation capabilities to prioritize and mitigate threats at internet scale and speed.
“Since 2005, I have been honored to be a member of the Cyveillance team. With decades of threat intelligence tradecraft experience and a state of the art 24x7 Cyber Security Center, Cyveillance brings a best-in-class data collection and vetting advantage over all other TI providers. This enriched Intelligence delivered within the ZeroFOX Platform will enable customers to achieve a new level of protection that is years ahead of the competition,” said James Carnall, Cyveillance General Manager. “I look forward to partnering with ZeroFOX to deliver timely, relevant and actionable threat intelligence. It’s clear that we will have the most robust Digital Risk Protection and Threat Intelligence portfolio available in the market.”
ZeroFOX will expand its service offerings for existing customers by leveraging the Cyveillance team, technology and their extensive collection of intelligence data. Existing Cyveillance customers will continue to receive custom Digital Risk Protection services and have access to the power of the ZeroFOX Digital Risk Protection Platform and its industry-leading remediation services.
Cyveillance capabilities include:
- Cyveillance Digital Risk Protection Services - A customer-centric Digital Risk Protection managed service that augments the force of information security teams looking to identify, analyze, and disrupt threats to critical assets and data.
- Cyveillance Data Lake - Cyveillance has the world's largest repository of cyber threat intelligence and threat actor information with more than 20 years of data assembled from the surface, deep, and dark web—powering enrichment, contextualization, API feeds, and threat hunting.
- Cyveillance Finished Intelligence - A digital library of actionable and relevant finished intelligence based on primary threat research and a proprietary intelligence data lake.
- Cyveillance Investigation, Analysis and Response Services - Custom investigation and analysis for physical and digital threats. Advanced analysts provide deep-dive reports, security forensics, threat assessments, research projects, and ad-hoc analyst projects. Projects are designed to dynamically apply and incorporate industry best practices into security and risk management programs.
As part of the acquisition, ZeroFOX will continue to exhibit leadership in this new cybersecurity era by establishing a world-class Cybersecurity Center of Excellence in the Washington, D.C., Metro Area with major offices in Reston, Virginia, and Baltimore, Maryland. This includes a state-of-the-art Cybersecurity Operations Center and Executive Briefing facility for demonstrating and leading organizations on cybersecurity trends, best practices, and technology innovations for Digital Risk Protection. ZeroFOX will also continue to grow its Centers of Excellence in the United Kingdom, Latin America, Asia and the Middle East with a focus on security operations and R&D.
ZeroFOX is trusted by global enterprises, serving thousands of customers, including more than 350 financial institutions in every major country. Funding by Intel Capital, NEA, Highland Capital Partners, Redline Capital Management, Hercules Capital, Comcast Ventures, and Core Capital, ZeroFOX has raised over $150 million in funding to date.
About ZeroFOX - ZeroFOX, the global category leader in Digital Risk Protection, safeguards modern organizations from dynamic security risks across the public attack surface including social media, mobile application, surface, deep and dark web, email and domains, and digital collaboration platforms. With complete global coverage and an artificial intelligence-based analysis engine, the ZeroFOX Platform identifies and remediates targeted phishing attacks, credential compromise, data exfiltration, brand hijacking, executive and location threats, and more. The patented ZeroFOX Platform technology processes and protects millions of posts, messages, and accounts daily across the social and digital landscape, spanning LinkedIn, Facebook, Slack, Instagram, Pastebin, YouTube, mobile app stores, domains, cloud-based email, and more.
About Cyveillance - Cyveillance, which was acquired by LookingGlass in 2015, has a rich history of providing customer-centric threat intelligence services to protect the most critical assets of enterprises worldwide. Founded in 1997, Cyveillance delivers an open source intelligence-led approach to security through continuous, comprehensive monitoring and analysis of millions of online data sources to protect client information, infrastructure, and employees from physical and online threats.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005690/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
